Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience-Reference-Cited by-同舟云学术

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience

Published:2019-01-03 Issue:1 Volume:12 Page:
ISSN:1756-8722
Container-title:Journal of Hematology & Oncology
language:en
Short-container-title:J Hematol Oncol

Author:

Chamoun Kamal,Kantarjian Hagop,Atallah Rami,Gonzalez Graciela Nogueras,Issa Ghayas C.,Rios Mary Beth,Garcia-Manero Guillermo,Borthakur Gautam,Ravandi Farhad,Jain Nitin,Daver Naval,Konopleva Marina,DiNardo Courtney D.,Kadia Tapan,Pemmaraju Naveen,Jabbour Elias,Cortes Jorge

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Biology,Hematology

Link

http://link.springer.com/content/pdf/10.1186/s13045-018-0686-1.pdf

Reference32 articles.

1. O’Brien SG, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994–1004.

2. Kantarjian H, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012;119(9):1981–7.

3. Cortes JE, et al. Bosutinib (BOS) versus imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): initial results from the BFORE trial. J Clin Oncol. 2017;35:7002.

4. Cortes JE, et al. Final 5-year study results of DASISION: the Dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–U54.

5. Hochhaus A, et al. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia. 2016;30(1):57–64.

Cited by 119 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sustainable new biosynthesis of Zero valence gold nanoparticles via Healthy Alchemilla vulgaris L. extract as capping agent;Case Studies in Chemical and Environmental Engineering;2024-12

2. Outcome after short exposure to tyrosine kinase inhibitors in pregnant female patients with chronic myeloid leukemia;Journal of Hematology & Oncology;2024-09-11

3. Nanostructured Hybrid Polymer‐Lipid Drug Delivery Platforms for Rapamycin Repositioning in Anticancer Therapy;Advanced Therapeutics;2024-08-07

4. Exploring novel circulating biomarkers for liver cancer through extracellular vesicle characterization with infrared spectroscopy and plasmonics;Analytica Chimica Acta;2024-08

5. Recent advances in nanostructure-enhanced optical assays focused on luminescence-based biosensors for detection of cancer biomarkers;TrAC Trends in Analytical Chemistry;2024-07